Premium
Brotizolam and chronic insomnia: a multi‐centre study.
Author(s) -
FritzOsner A,
AriasOrtiz JL,
Dorantes JF,
RabagoSanchez J,
Rodriguez Tenorio A,
SanchezMartinez J
Publication year - 1983
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1983.tb02319.x
Subject(s) - insomnia , chronic insomnia , medicine , physical therapy , pharmacology , sleep disorder
A double‐blind, crossover study was carried out on the acceptability of three doses of brotizolam (0.125, 0.25 and 0.5 mg) in chronic insomniacs aged between 21 and 75 years (33 men: 42 women). Patients reported a shorter time to fall asleep and less nocturnal awakenings. Improvement in sleep was evident during the first week of the study when each patient received 0.25 mg. There were no dose‐related side‐ effects, and on withdrawal from the medication there was no evidence of disturbed sleep which would have suggested a rebound effect.